This clinical trial is focused on studying the treatment of community-acquired pneumonia, a type of lung infection that is acquired outside of a hospital setting. The trial will use a medication called Clarithromycin, which is a type of antibiotic that helps fight bacterial infections. The purpose of the study is to determine if early treatment with Clarithromycin, guided by specific biomarkers, can prevent the progression of pneumonia into a more severe condition known as sepsis.
Participants in the study will be randomly assigned to receive either Clarithromycin or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of up to seven days, during which participants will take the medication orally in the form of film-coated tablets. The trial aims to optimize the benefits of Clarithromycin treatment and provide evidence for its effectiveness in preventing sepsis in patients at risk.
Throughout the study, participants will be monitored for changes in their symptoms and overall health. The trial will assess whether the treatment helps reduce symptoms such as cough, difficulty breathing, and chest pain, and whether it prevents the development of new organ dysfunctions. The study will also evaluate the need for additional antibiotics and the overall recovery of participants, including their discharge from the hospital. The findings from this trial could provide valuable insights into the management of community-acquired pneumonia and its complications.
Greece 